As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...

A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value ...

Lina Polimeni, chief corporate brand officer at Lilly, notes that public perception of the company has historically been ...

Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...

Boyd Watterson Asset Management LLC OH trimmed its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 9.3% during ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

Beijing is emerging as a global hub for pharmaceutical innovation as eight international pharmaceutical companies plan to establish research and development centers in the city.